TY - JOUR
T1 - Isolation and Characterization of L-Asparaginase-Producing Bacteria from the Arabian–Persian Gulf Region
T2 - First Report on Bacillus xiamenensis ASP-J1-4 as a Producer and Its Potential Application
AU - Al-Harbi, Ghofran M.
AU - Kotb, Essam
AU - Almiman, Abeer A.
AU - Berekaa, Mahmoud M.
AU - Alhamad, Salwa
AU - Alahmady, Nada F.
AU - Aljafary, Meneerah A.
AU - Alqazlan, Nadiyah M.
AU - Alyami, Reem I.
AU - Alqarni, Joud M.
AU - Al-Suhaimi, Ebtesam Abdullah
N1 - Publisher Copyright:
© 2025 by the authors.
PY - 2025/5
Y1 - 2025/5
N2 - L-asparaginase (L-ASNase) functions as a chemotherapeutic enzyme with antitumor properties. It facilitates the degradation of L-asparagine (L-ASN), a vital amino acid required for the proliferation of tumor cells. In this study, we have isolated 177 L-ASNase-producing strains from the aquatic environment of the Arabian–Persian Gulf. The most potent isolate, ASP-J1-4, was an endophyte recovered from the seablite Suaeda maritima and was molecularly identified as B. xiamenensis (accession number PQ593941). The enzyme purified through DEAE-Sepharose displayed a molecular weight of 37 kDa based on the SDS-PAGE profile and lacked detectable L-glutaminase (L-GTNase) activity. Optimal enzyme activity was at 40 °C and pH 9.0, with stability at pH 7–9. The maximum stimulation effect was found in the presence of Fe3+, Mn2+, and Na+ ions, respectively. The enzyme demonstrated a Vmax of 35.71 U/mL and a Km of 0.15 mM. Interestingly, ASP-J1-4 L-ASNase showed a dose-dependent inhibition against human colon carcinoma (HCT-116) and cervical Henrietta Lacks (HeLa) cell lines, with IC50 values of 15.42 µg/mL and 12.13 µg/mL, respectively. These findings collectively suggest a biocompatible, efficient, and robust enzyme for potential applications in tumor therapy after validation of in vivo studies and clinical trials. This study introduces the first deep screening program for L-ASNase-producing bacteria harboring in the Arabian–Persian Gulf region. In addition, it launches B. xiamenensis and other species as new sources of L-ASNase.
AB - L-asparaginase (L-ASNase) functions as a chemotherapeutic enzyme with antitumor properties. It facilitates the degradation of L-asparagine (L-ASN), a vital amino acid required for the proliferation of tumor cells. In this study, we have isolated 177 L-ASNase-producing strains from the aquatic environment of the Arabian–Persian Gulf. The most potent isolate, ASP-J1-4, was an endophyte recovered from the seablite Suaeda maritima and was molecularly identified as B. xiamenensis (accession number PQ593941). The enzyme purified through DEAE-Sepharose displayed a molecular weight of 37 kDa based on the SDS-PAGE profile and lacked detectable L-glutaminase (L-GTNase) activity. Optimal enzyme activity was at 40 °C and pH 9.0, with stability at pH 7–9. The maximum stimulation effect was found in the presence of Fe3+, Mn2+, and Na+ ions, respectively. The enzyme demonstrated a Vmax of 35.71 U/mL and a Km of 0.15 mM. Interestingly, ASP-J1-4 L-ASNase showed a dose-dependent inhibition against human colon carcinoma (HCT-116) and cervical Henrietta Lacks (HeLa) cell lines, with IC50 values of 15.42 µg/mL and 12.13 µg/mL, respectively. These findings collectively suggest a biocompatible, efficient, and robust enzyme for potential applications in tumor therapy after validation of in vivo studies and clinical trials. This study introduces the first deep screening program for L-ASNase-producing bacteria harboring in the Arabian–Persian Gulf region. In addition, it launches B. xiamenensis and other species as new sources of L-ASNase.
KW - Arabian–Persian Gulf
KW - Bacillus xiamenensis
KW - L-asparaginase
KW - antitumor
KW - marine bacteria
KW - marine drugs
UR - https://www.scopus.com/pages/publications/105006749037
U2 - 10.3390/md23050194
DO - 10.3390/md23050194
M3 - Article
C2 - 40422784
AN - SCOPUS:105006749037
SN - 1660-3397
VL - 23
JO - Marine Drugs
JF - Marine Drugs
IS - 5
M1 - 194
ER -